17-n-n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one has been researched along with 6-methylene-4-pregnene-3-20-dione* in 2 studies
2 other study(ies) available for 17-n-n-diethylcarbamoyl-4-methyl-4-azaandrostane-3-one and 6-methylene-4-pregnene-3-20-dione
Article | Year |
---|---|
In vivo assay for conversion of testosterone to dihydrotestosterone by rat prostatic steroid 5 alpha-reductase and comparison of two inhibitors.
An in vivo assay for steroid 5 alpha-reductase in rat ventral prostate has been developed and used to compare the inhibitory activity of N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxamide (4-MA) and 6-methylene-4-pregnene-3,20-dione (LY207320). Immature rats (70-80 g) received test compounds 30 min prior to s.c. injection of [3H]-T. The rats were sacrificed 30 min later and the ventral prostates were analyzed for [3H]-T metabolites. Intraprostatic [3H]-T and [3H]-DHT reached peak levels within 5 min after injection of [3H]-T and declined to about 25% of peak levels after 2 hr. 4-MA was a very potent inhibitor of [3H]-DHT formation with an estimated IC50 of 0.2 mg/kg. LY207320, an inhibitor of 5 alpha-reductase in vitro, was weakly active in vivo and did not achieve greater than 45% inhibition at high doses (greater than 200 mg/kg, s.c.). Tissue uptake of [3H]-T was also inhibited by LY207320, which may contribute to its inhibitory activity on accessory sex organ growth in the rat. Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Azasteroids; Chromatography, High Pressure Liquid; Dihydrotestosterone; Dose-Response Relationship, Drug; Male; Progesterone; Prostate; Rats; Rats, Inbred F344; Testosterone; Time Factors; Tritium | 1991 |
Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration.
Mouse prostatic hyperplasia has been induced experimentally by implanting fetal urogenital sinus tissue into the prostate gland of syngeneic mice. We compared the effects of castration and steroid antagonist administration on the growth of the prostate gland during both the early (15 days) and late (30 days) phases of prostatic enlargement. Castration at the time of induction of prostatic hyperplasia is by far the most effective method of inhibiting prostatic overgrowth. A comparison of castration for 7 days with the short-term (7 days) administration of steroid antagonists showed that during the early phase of prostatic enlargement castration is more effective than antiandrogen, which is more effective than 5 alpha-reductase inhibitors. In the late phase of mouse prostatic enlargement, castration for 7 days is less effective than treatment with either antiandrogen or a 5 alpha-reductase inhibitor. Our data indicate that treatment with a combination of an antiestrogen (keoxifene) with a 5 alpha-reductase inhibitor (in particular, 6-methylene progesterone) is the most effective combination for reducing prostatic overgrowth. The antiestrogen (keoxifene) treatment alone was ineffective in both the early and late phases of prostatic overgrowth. Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Azasteroids; Dihydrotestosterone; DNA; Drug Therapy, Combination; Estrogen Antagonists; Female; Male; Mice; Mice, Inbred BALB C; Orchiectomy; Piperidines; Progesterone; Prostatic Hyperplasia; Raloxifene Hydrochloride; Urogenital System | 1990 |